{
    "nct_id": "NCT06868485",
    "official_title": "A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with First-Line Osimertinib Treatment and Harbor a C797S Mutation",
    "inclusion_criteria": "Inclusion criteria:\n\n* Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling and analyses.\n* Male or female aged â‰¥18 years old.\n* Histological or cytological confirmation diagnosis of NSCLC.\n* Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.\n* Evidence of radiological disease progression while on a previous continuous treatment with first-line Osimertinib treatment.\n* Documented EGFR mutation .\n* Eastern Cooperative Oncology Group (ECOG) 0-1 and a minimum life expectancy of 12 weeks.\n* At least one lesion, not previously irradiated and not chosen for biopsy during the study.\n* Females should have evidence of non-childbearing potential.\n\nExclusion criteria:\n\n* Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.\n* Any unresolved toxicities from prior therapy greater than CTCAE Grade 1.\n* Symptomatic brain complications that require urgent neurosurgical or medical intervention.\n* Any evidence of severe or uncontrolled systemic diseases.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection.\n* Past medical history of ILD.\n* Inadequate bone marrow reserve or organ function as demonstrated.\n* Males and females of reproductive potential.\n* Known intracranial hemorrhage which is unrelated to tumor.\n* Seizures requiring a change in anti-epileptic medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}